Lisata Therapeutics, Inc. - Common Stock LSTA 深 滬
等待開盤 12-25 09:30:00 美东时间
2.05
-0.020
-0.97%
華盛通- 最 高2.06
- 今 開2.06
- 成交量 1.81万股
- 最 低 2.01
- 昨 收 2.07
- 總市值 1808.24万
- 52周最高 4.20
- 市盈率 靜 --
- 換手率 0.20%
- 52周最低 1.81
- 委 比 83.42%
- 總股本 882.07万
- 歷史最高 1483.50
- 量 比 0.78
- 振 幅 2.42%
- 歷史最低 1.81
- 每 手 1
- 風險率 0.38%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多电话会总结 ｜ Lisata(LSTA)2025财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Lisata Therapeutics 2025年第三季度业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **运营费用表现：** - 2025年第三季度运营费用为440万美元，较2024年同期的530万美元下降90万美元 - 研发费用为200万美元，较2024年同期的250万美元减少60万美元 - 一般管理费用为250万美元，较2024年同期的280万美元减少30万美元 - 净亏损为420万美元，较2024年同期的490万美元有所改善 **现金状况：** - 截至2025年第三季度末，现金及现金等价物为1900万美元 - 公司预计现有
11-10 12:01
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’
<p>Lisata Therapeutics, Inc. has been recognized with the “Overall BioPharma Solution of the Year” award for the second consecutive year by BioTech Breakthrough. The company was honored for its innovative CendR Platform technology, which enhances the delivery of anti-cancer drugs to solid tumors, improving their efficacy. Lisata's certepetide has shown promising results in clinical trials, including high response rates in pancreatic cancer. The a...
11-06 13:00
Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
<p>Lisata Therapeutics, Inc. (Nasdaq: LSTA) announced it will report third-quarter 2025 financial results on November 6, 2025, after market close, and host a conference call at 4:30 p.m. Eastern Time. Participants can join via toll-free dial (800) 715-9871 or international dial (646) 307-1963, using conference ID 6375221. A live webcast will be available on the company’s website under the Investors & News section, with a replay accessible for 12 ...
10-30 12:00
Lisata Therapeutics Highlights Cancer Therapy Innovations
Lisata Therapeutics ( ($LSTA) ) just unveiled an update. On October 14, 2025, L...
10-15 04:37
Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement
Lisata Therapeutics and Catalent have entered a global license agreement to develop certepetide as payloads in Catalent’s SMARTag ADC platform for treating difficult-to-treat diseases. Catalent gains rights to evaluate certepetide and its analogs across multiple ADCs, with Lisata eligible for over $10M in milestones and revenue sharing. The collaboration leverages certepetide’s potential to enhance tumor targeting and treatment outcomes, supporte...
10-08 12:30
Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial
Lisata Therapeutics announced promising preliminary results from its Phase 1/2a CENDIFOX trial combining certepetide with FOLFIRINOX for pancreatic ductal adenocarcinoma (PDAC). Among 35 patients, 10 achieved R0 resection with 50% success and 70% experienced partial tumor response. The two-year overall survival rate was 60%, with a 12-month median disease-free survival. Enhanced immune cell infiltration and increased PD-1, PD-L1 expression indica...
09-29 12:00
Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Lisata Therapeutics announced that its CEO, David J. Mazzo, Ph.D., will provide a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference in New York City on September 8-10, 2025. The presentation will be available on-demand starting September 5, 2025, at 7:00 a.m. ET. Lisata, a clinical-stage pharmaceutical company, focuses on developing innovative therapies for advanced solid tumors. Its drug candidate, certepetide, a...
09-02 12:00
HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Lisata Therapeutics (NASDAQ:LSTA) with a Buy and maintains $15 price target.
08-21 19:18
Lisata Therapeutics Reports Strong Q2 2025 Financials
The latest announcement is out from Lisata Therapeutics ( ($LSTA) ). On August ...
08-08 04:43
